Anti-seizure Therapy STK-001 Safe, Showing Hints of Efficacy in Trial

Anti-seizure Therapy STK-001 Safe, Showing Hints of Efficacy in Trial

312699

Anti-seizure Therapy STK-001 Safe, Showing Hints of Efficacy in Trial

Treatment with STK-001, Stoke Therapeutics‘ investigational therapy for Dravet syndrome, has so far raised no safety concerns among children taking part in the ongoing Phase 1/2a MONARCH clinical trial, according to the results of a planned interim analysis. Early data also hint that the medication may reduce seizure frequency among trial participants. “The initial positive safety data from MONARCH are highly encouraging,” Barry Ticho, MD, PhD, Stoke’s chief medical officer, said in a press release.…

You must be logged in to read/download the full post.